News tagged with vyndaqel
Tafamidis: Approval denotes proven added benefit
Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with ...
Medications
Sep 17, 2012 |
not rated yet |
0
Study reveals how the world's first drug for amyloid disease works
Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works. Tafamidis, approved for use in Europe and currently under ...
Medical research
May 29, 2012 |
5 / 5 (3) |
0
|
